Effect of Vancomycin Minimal Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Endocarditis
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Staphylococcus aureus endocarditis has a high mortality rate. Vancomycin minimum inhibitory concentration (MIC) has been shown to affect the outcome of methicillin-resistant S. aureus bacteremia, and recent data point to a similar effect on methicillin-susceptible S. aureus bacteremia. We aimed to evaluate the effect of vancomycin MIC on left-sided S. aureus infective endocarditis (IE) treated with cloxacillin. METHODS: We analyzed a prospectively collected cohort of patients with IE in a single tertiary-care hospital. Vancomycin, daptomycin, and cloxacillin MIC was determined by E-test. S. aureus strains were categorized as low vancomycin MIC (<1.5 µg/mL) and high vancomycin MIC (≥1.5 µg/mL). The primary endpoint was in-hospital mortality. RESULTS: We analyzed 93 patients with left-sided IE treated with cloxacillin, of whom 53 (57%) had a vancomycin MIC < 1.5 µg/mL and 40 (43%) a vancomycin MIC ≥ 1.5 µg/mL. In-hospital mortality was 30% (n = 16/53) in patients with a low vancomycin MIC and 53% (n = 21/40) in those with a high vancomycin MIC (P = .03). No correlation was found between oxacillin MIC and vancomycin or daptomycin MIC. Logistic regression analysis showed that higher vancomycin MIC increased in-hospital mortality 3-fold (odds ratio, 3.1; 95% confidence interval, 1.2-8.2) after adjustment for age, year of diagnosis, septic complications, and nonseptic complicated endocarditis. CONCLUSIONS: Our results indicate that vancomycin MIC could be used to identify a subgroup of patients with methicillin-susceptible S. aureus IE at risk of higher mortality. The worse outcome of staphylococcal infections with a higher vancomycin MIC cannot be explained solely by suboptimal pharmacokinetics of antibiotics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, this association between higher vancomycin MIC in infecting MSSA and worse clinical outcomes among patients treated with antistaphylococcal penicillins (not vancomycin) was externally validated in a large cohort of patients with MSSA IE. 142”
Citations
Cites
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995 · cited 1×
“Definitions Conference [13].”
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 1×
“Definitions The diagnosis of confirmed endocarditis was based on the modified Duke criteria [12].”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362 · cited 1×
“Staphylococcus aureus is the leading cause of infective endocarditis (IE) worldwide [1].”
BackgroundBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Staphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 2×
“and 1 meta-analysis have confirmed this association with MRSA bacteremia treated with vancomycin [4–6].”
BackgroundRybak, M. J., Lomaestro, B. M., Rotscahfer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Clinical Infectious Diseases · doi:10.1086/600877 · Cited by 815 · cited 1×
“MRSA bacteremia with a vancomycin MIC of 2 μg/mL using a dose of vancomycin of 15 mg/kg/12 hours we would have trough concentrations and AUC/MIC ratio around 10 mg/L and 200, respectively [16], which is clearly under the ideal threshold of clinical efficacy, it is recommended to increase the vancomycin dose to achieve…”
MethodSoriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J. (2008) · Clinical Infectious Diseases · doi:10.1086/524667 · Cited by 767 · cited 2×
“and 1 meta-analysis have confirmed this association with MRSA bacteremia treated with vancomycin [4–6].”
BackgroundSelf-citationvan Hal, S. J., Lodise, T. P., & Paterson, D. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir935 · Cited by 512
Miro, J. M., Anguera, I., Cabell, C. H., Chen, A. Y., Stafford, J. A., Corey, G. R., Olaison, L., Eykyn, S., Hoen, B., Abrutyn, E., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/431979 · Cited by 334
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O’Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Gao, W., Christiansen, K. J., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir270 · Cited by 228 · cited 6×
“This study tried to confirm the previous results of Holmes et al [8] in patients with S. aureus bacteremia, for whom vancomycin MIC was an independent risk factor for mortality regardless of the antibiotic regimen administered.”
BackgroundResultInfluentialEpistatic Relationships between sarA and agr in Staphylococcus aureus Biofilm Formation
Beenken, K. E., Mrak, L. N., Griffin, L. M., Zielinska, A. K., Shaw, L. N., Rice, K. C., Horswill, A. R., Bayles, K. W., & Smeltzer, M. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010790 · Cited by 194 · cited 1×
“[24]showed that mutations in agr lead to increased biofilm formation (and a subsequent increased risk of embolism) and decreased antibiotic susceptibility.”
BackgroundFowler, V. G., Nelson, C. L., McIntyre, L. M., Kreiswirth, B. N., Monk, A., Archer, G. L., Federspiel, J., Naidich, S., Remortel, B., Rude, T., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/520088 · Cited by 153
Nienaber, J. J. C., Sharma Kuinkel, B. K., Clarke-Pearson, M., Lamlertthon, S., Park, L., Rude, T. H., Barriere, S., Woods, C. W., Chu, V. H., Marín, M., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir389 · Cited by 152 · cited 1×
“However, most MSSA CCs involved in the development of endocarditis in a local study [20] and an international study [21] were CC30 and, to a lesser extent, CC5.”
BackgroundDeLeo, F. R., Kennedy, A. D., Chen, L., Wardenburg, J. B., Kobayashi, S. D., Mathema, B., Braughton, K. R., Whitney, A. R., Villaruz, A. E., Martens, C. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111084108 · Cited by 149 · cited 2×
“aureus CC30 agrC and hla that restrict this microorganism to the hospital setting, where it can cause endocarditis in morecompromised hosts [23].”
BackgroundFederspiel, J. J. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1027 · Cited by 129
Bae, I., Federspiel, J. J., Miró, J. M., Woods, C. W., Park, L., Rybak, M. J., Rude, T. H., Bradley, S., Bukovski, S., de la Maria, C. G., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/606027 · Cited by 122 · cited 1×
“The results of the only study to analyze the effect of vancomycin MIC on the outcome of MRSA endocarditis [7] revealed more frequent persistent bacteremia and a higher incidence of heart failure and mortality when the vancomycin MIC was >1.”
BackgroundSelf-citationHigh Vancomycin MIC and Complicated Methicillin-SusceptibleStaphylococcus aureusBacteremia
Aguado, J. M., Juan, R. S., Lalueza, A., Sanz, F., Otero, J. R., Gómez-González, C., & Cháves, F. (2011) · Emerging infectious diseases · doi:10.3201/eid/1706.101037 · Cited by 76 · cited 1×
“A strong association between vancomycin MIC and the outcome of MSSA bacteremia was recently reported, regardless of the antibiotic treatment administered (antistaphylococcal penicillin or vancomycin) [8, 9].”
BackgroundGarcía-de-la-Mària, C., Marco, F., Armero, Y., Soy, D., Moreno, A., del Río, A., Almela, M., Cervera, C., Ninot, S., Falces, C., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01011-09 · Cited by 68 · cited 1×
“of MRSA in vegetations between animals treated with the recommended doses of vancomycin and those treated with higher doses [18].”
BackgroundSelf-citationInfluence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection
Scaglione, F., & Paraboni, L. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.3.479 · Cited by 58 · cited 1×
“MRSA bacteremia with a vancomycin MIC of 2 μg/mL using a dose of vancomycin of 15 mg/kg/12 hours we would have trough concentrations and AUC/MIC ratio around 10 mg/L and 200, respectively [16], which is clearly under the ideal threshold of clinical efficacy, it is recommended to increase the vancomycin dose to achieve…”
MethodMarco, F., García de la Mària, C., Armero, Y., Amat, E., Soy, D., Moreno, A., del Río, A., Almela, M., Mestres, C. A., Gatell, J. M., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00510-07 · Cited by 58 · cited 1×
“However, in experimental models of MRSA endocarditis caused by strains with a vancomycin MIC of 2 μg/mL, no statistically significant differences were found in the percentage of sterile vegetations or the number of colony-forming units of MRSA in vegetations between animals treated with the recommended doses of vancom…”
BackgroundSelf-citationGill, S. R., McIntyre, L. M., Nelson, C. L., Remortel, B., Rude, T., Reller, L. B., & Fowler, V. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018673 · Cited by 42 · cited 5×
“However, because this association between S. aureus CC30 and endocarditis was found in 2 studies from 1994–2003 and 2000–2006, there are no data to support that CC30 is now associated with a higher risk of endocarditis.”
BackgroundInfluentialMiller, C. E., Batra, R., Cooper, B. S., Patel, A., Klein, J. L., Otter, J. A., Kypraios, T., French, G. L., Tosas, O., & Edgeworth, J. D. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir858 · Cited by 41 · cited 2×
“The same trend was observed by Miller et al [15] in the United Kingdom in 821 consecutive episodes of MRSA bacteremia diagnosed between 1999 and 2009.”
MethodViedma, E., Sanz, F., Orellana, M. Á., Juan, R. S., Aguado, J. M., Otero, J. R., & Cháves, F. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt337 · Cited by 30
Holmes, N. E., Turnidge, J. D., Munckhof, W., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S., Warren, S. J. C., Gao, W., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12168 · Cited by 28 · cited 1×
“justment for comorbidities and disease severity [10].”
High Vancomycin MIC and Complicated Methicillin-SusceptibleStaphylococcus aureusBacteremia
Aguado, J. M., Juan, R. S., Lalueza, A., et al. (2011) · Emerging infectious diseases · doi:10.3201/eid1706.101037 · Cited by 18
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Management Considerations in Infective Endocarditis: A Review
Wang, A., Gaca, J. G., & Chu, V. H. (2018) · JAMA · doi:10.1001/jama.2018.7596 · Cited by 368
Staphylococcus aureusbacteraemia and endocarditis – epidemiology and outcome: a review
Ásgeirsson, H., Thalme, A., & Weiland, O. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1392039 · Cited by 163
“Long-term mortality after SAE is not very well described, but a 1-year mortality rate of 19–44% has been observed [65,110,113,178,179,181,182].”
BackgroundDiaz, R., Afreixo, V. M. A., Ramalheira, E., Rodrigues, C., & Gago, B. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.06.017 · Cited by 101
Metadata
- Authors
- Cervera, C., Castaneda, X., de la Maria, C. G., del Rio, A., Moreno, A., Soy, D., Pericas, J. M., Falces, C., Armero, Y., Almela, M., Ninot, S., Pare, J. C., Mestres, C. A., Gatell, J. M., Marco, F., Miro, J. M., The Hospital Clinic Endocarditis Study Group, Miro, J. M., Moreno, A., del Rio, A., Cervera, C., Pericas, J. M., Castaneda, X., Gatell, J. M., Marco, F., Almela, M., Jimenez-de-Anta, M. T., de la Maria, C. G., Armero, Y., Mestres, C. A., Pare, J. C., Falces, C., Cartana, R., Ninot, S., Azqueta, M., Sitges, M., Heras, M., Pomar, J. L., Ramirez, J., Ribalta, T., Brunet, M., Soy, D., & Llopis, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-18
- Volume
- 58
- Issue
- 12
- Pages
- 1668-1675
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113688823
- Semantic Scholar
- 4f9f34df6f671ca460fe94e76c0b861a6421abe4
- Cited by
- 61
- References
- 25
- Citations by year
- 2026: 1 · 2025: 3 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 8 · 2016: 10 · 2015: 16 · 2014: 4
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- methicillin-susceptible Staphylococcus aureus, infective endocarditis, in-hospital mortality, cloxacillin, daptomycin, antibiotic susceptibility, left-sided endocarditis, septic complications
- MeSH terms
- Adult, Aged, Anti-Bacterial Agents, Cloxacillin, Endocarditis, Bacterial, Female, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Survival Rate, Hospital Mortality, Daptomycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.